Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukes' C Colon Cancer: Economic Evaluation in an Italian NHS Setting

Author： Francesco Di Costanzo  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.28, Iss.10, 2008-01, pp. : 645-655

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Adding Folinic Acid to Fluorouracil Plus Levamisole as Adjuvant Chemotherapy in Patients with Colon Cancer in Germany

By Monz B.U.M.  

PharmacoEconomics, Vol. 21, Iss. 10, 2003-01 ,pp. : 709-719

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Capecitabine Compared with Bolus 5-Fluorouracil/l-Leucovorin for the Adjuvant Treatment of Colon Cancer in Japan

By Shiroiwa Takeru  

PharmacoEconomics, Vol. 27, Iss. 7, 2009-07 ,pp. : 597-608

Adis International

Access to resources Recommend Favorite

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

By Madajewicz Stefan  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 772-778

Springer Publishing Company

Access to resources Recommend Favorite

Capecitabine dominant in Dukes' C colon cancer

By  

Inpharma, Vol. 1, Iss. 1658, 2008-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Capecitabine dominant in Dukes' C colon cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 563, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite